Smart, actionable news trusted by millions.
Delivering exclusive news and sharp analysis on finance and investing—all for free.
JUST FOR FUN
pic.twitter.com/78EOOhNmrS— Brisk God (@brisk_god) March 7, 2024
pic.twitter.com/78EOOhNmrS
State officials greenlit three new casino projects in New York City on Monday, setting the stage for a new era of gambling in the Big Apple.
The way advisors communicate retirement outcomes can dramatically improve client optimism.
US shoppers are now paying an average price of $6.60 per pound of ground beef, according to the US Bureau of Labor Statistics.
Gone are the days where you had to wander endless thrift stores and sift through racks to find the perfect pair of previously owned jeans.
Anduril was last valued at $30 billion in June, when its $2.5 billion fundraising round was oversubscribed eight times.
Asset managers acknowledge the reality of paying to access Schwab customers, as they have started to do with Fidelity.
The success of indie titles may help video game makers rely less on blockbusters and widen creative license, creating a 1UP for players.
As active ETFs have exploded, so too has thematic investing, a dangerous trend for most investors, the author of a Morningstar report said.
Some products don’t have the capital to get off the ground. Larger ETF issuers can fix that.
New tax laws including the One Big Beautiful Bill Act present novel risks and opportunities when filing next year’s tax returns.
Artificial intelligence can do a lot of things. Getting us on an exercise bike doesn’t appear to be one of them.
Glimpse into the future of technology.
Kohl’s is the largest US department store chain by number of retail locations, with more than double the number operated by Macy’s.
Gemini was trained on Google’s in-house chips, which look like a cheaper and more efficient alternative to Nvidia’s cutting-edge products.
The bond ladder ETFs come with a target date and can help advisors build income for clients’ major life events.
The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.